Papers by El-Nasir Lalani
Neoplasia, 2008
Bookmarks Related papers MentionsView impact
European Urology Supplements, 2003
Bookmarks Related papers MentionsView impact
Human Pathology, 2002
Bookmarks Related papers MentionsView impact
Translational Oncology, 2014
Bookmarks Related papers MentionsView impact
European Urology Supplements, 2003
Bookmarks Related papers MentionsView impact
European Urology Supplements, 2003
Bookmarks Related papers MentionsView impact
European Urology Supplements, 2003
Bookmarks Related papers MentionsView impact
European Urology Supplements, 2003
Bookmarks Related papers MentionsView impact
American Review of Respiratory Disease, 1991
Although mucins have been studied at the biochemical and biophysical level for some time, attempt... more Although mucins have been studied at the biochemical and biophysical level for some time, attempts to define their structures in detail were only partially successful because of their size and complexity. The advent of monoclonal antibodies reactive with these molecules introduced a new approach to structural studies by defining antigenic epitopes, by allowing purification of the mucin molecules by affinity chromatography, and by providing a means to clone genes coding for the core proteins. By their profile of reactivity with the normal and cancer-associated mucin in a particular tissue, the antibodies also defined a difference in the mucin derived from the two sources. It is now clear that this difference lies in the carbohydrate side chains, as the core proteins are identical. Because the mucins are tumor-associated antigens and the cancer mucins can express epitopes that are relatively tumor specific, this family of molecules is now being intensively studied. There is also considerable interest in elucidating the normal function of the mucin and in determining whether, through an altered structure, this function is subverted in malignancy. In the next few years we should expect that the structure of other mucins will be defined in the same detail as the product of the MUC1 gene. We should also expect to see the continued application of mucin-reactive antibodies in the clinic and the investigation of mucins as agents for immunotherapy of some cancers. As to the function(s) of these molecules, perhaps we will learn enough in the future to make a critical reappraisal of the name.
Bookmarks Related papers MentionsView impact
Peptides, 2004
Bookmarks Related papers MentionsView impact
Peptides, 2004
Bookmarks Related papers MentionsView impact
Nuclear Medicine Communications, 1998
Bookmarks Related papers MentionsView impact
Neoplasia, 2003
Bookmarks Related papers MentionsView impact
Nature Clinical Practice Oncology, 2006
Bookmarks Related papers MentionsView impact
Molecular Human Reproduction, 2001
Bookmarks Related papers MentionsView impact
Molecular Endocrinology, 2003
Recent work indicates that thyroid hormone receptor-associated protein 220 (TRAP220), a subunit o... more Recent work indicates that thyroid hormone receptor-associated protein 220 (TRAP220), a subunit of the multiprotein TRAP coactivator complex, is essential for embryonic survival. We have generated TRAP220 conditional null mice that are hypomorphic and express the gene at reduced levels. In contrast to TRAP220 null mice, which die at embryonic d 11.5 (E11.5), hypomorphic mice survive until E13.5. The reduced expression in hypomorphs results in hepatic necrosis, defects in hematopoiesis, and hypoplasia of the ventricular myocardium, similar to that observed in TRAP220 null embryos at an earlier stage. The embryonic lethality of null embryos at E11.5 is due to placental insufficiency. Tetraploid aggregation assays partially rescues embryonic development until E13.5, when embryonic loss occurs due to hepatic necrosis coupled with poor myocardial development as observed in hypomorphs. These findings demonstrate that, for normal placental function, there is an absolute requirement for TRA...
Bookmarks Related papers MentionsView impact
Molecular Cancer Research, 2009
The tetraspanin CD151 forms stoichiometric complexes with laminin-binding integrins (e.g., α3β1, ... more The tetraspanin CD151 forms stoichiometric complexes with laminin-binding integrins (e.g., α3β1, α6β1, and α6β4) and regulates their ligand-binding and signaling functions. We have found that high expression of CD151 in breast cancers is associated with decreased overall survival (3.44-fold higher risk of death). Five-year estimated survival rates were 45.8% (95% confidence interval, 16.4-71.4%) for CD151-positive patients and 79.9% (95% confidence interval, 62.2-90.0%) for CD151-negative patients. Furthermore, CD151 was positively associated with axillary lymph node involvement. To study the biological significance of this observation, we investigated the contribution of CD151 in breast cancer tumorigenesis using MDA-MB-231 cells as a model system. Stable down-regulation of this tetraspanin by short-hairpin RNA decreased the tumorigenicity of these cells in mice. Detailed immunohistologic analysis of CD151(+) and CD151(−) xenografts showed differences in tumor vascular pattern. Vas...
Bookmarks Related papers MentionsView impact
The Lancet, 2001
Bookmarks Related papers MentionsView impact
Journal of Urology, 2005
Oral estrogens were an effective treatment for prostate cancer but were abandoned because of an i... more Oral estrogens were an effective treatment for prostate cancer but were abandoned because of an increased risk of cardiovascular toxicity and particularly thromboembolism. We have recently shown that transdermal estradiol produces an effective tumor response and negligible cardiovascular toxicity. Here we report the influence of transdermal estradiol therapy on the coagulation profile of men with advanced prostate cancer. A total of 20 patients with newly diagnosed locally advanced or metastatic prostate cancer were treated using transdermal estradiol patches and the coagulation profile was assessed before and during 12 months therapy. Activation of coagulation was assessed by assaying the levels of activated factor VII (VIIa), activated factor XII (XIIa), prothrombin fragments 1 and 2 (F1 + 2), thrombin-antithrombin III (TAT III) complex and fibrinogen. Inhibition of the coagulation cascade was assayed by protein C, protein S and activated protein C resistance (APC-R). Fibrinolytic activity was determined by assaying tissue plasminogen activator (TPA) and plasminogen activation inhibitor type 1 (PAI-1). D-Dimer levels assessed both coagulation and fibrinolytic (thrombophilic) activity. Venous Duplex, color Doppler ultrasound and photoplethysmography were used to assess for thrombosis. Levels of VIIa and XIIa were unaffected by transdermal estradiol therapy. Although levels of TAT III were increased in some patients at 12 months, the increase was markedly less than that observed historically with equivalent doses of oral estrogens. Levels of the inhibitory and fibrinolytic factors including protein C, protein S, APC-R, TPA and PAI-1 remained stable. Reductions in F1+F2, fibrinogen and D-Dimer levels represented a normalization from increased levels to the physiological range. These results suggest that transdermal estradiol reduces thrombophilic activation in men with advanced prostate cancer, and protects against the risk of thrombosis.
Bookmarks Related papers MentionsView impact
Journal of Hepatology, 1997
Bookmarks Related papers MentionsView impact
Uploads
Papers by El-Nasir Lalani